NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceutical products using micellar nanoparticle technology primarily for the treatment of cancer in Japan.
Flawless balance sheet and overvalued.
Share Price & News
How has NanoCarrier's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 3NQ's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 3NQ underperformed the German Biotechs industry which returned 10% over the past year.
Return vs Market: 3NQ underperformed the German Market which returned 12.8% over the past year.
Price Volatility Vs. Market
How volatile is NanoCarrier's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is NanoCarrier undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 3NQ's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 3NQ's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 3NQ is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 3NQ is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 3NQ's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 3NQ is good value based on its PB Ratio (1.8x) compared to the DE Biotechs industry average (3.5x).
How is NanoCarrier forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NanoCarrier has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine NanoCarrier's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- NanoCarrier competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has NanoCarrier performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3NQ is currently unprofitable.
Growing Profit Margin: 3NQ is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 3NQ is unprofitable, and losses have increased over the past 5 years at a rate of -15.1% per year.
Accelerating Growth: Unable to compare 3NQ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 3NQ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 3NQ has a negative Return on Equity (-15.69%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is NanoCarrier's financial position?
Financial Position Analysis
Short Term Liabilities: 3NQ's short term assets (¥8.2B) exceed its short term liabilities (¥149.0M).
Long Term Liabilities: 3NQ's short term assets (¥8.2B) exceed its long term liabilities (¥28.0M).
Debt to Equity History and Analysis
Debt Level: 3NQ is debt free.
Reducing Debt: 3NQ has no debt compared to 5 years ago when its debt to equity ratio was 3.9%.
Inventory Level: 3NQ has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 3NQ's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 3NQ has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 3NQ has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -16.1% each year
What is NanoCarrier's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 3NQ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 3NQ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 3NQ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 3NQ's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 3NQ's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Tetsuhito Matsuyama 0
Mr. Tetsuhito Matsuyama is President & Director since November 2019 and had been the Chief Financial Officer and Head of Chief Executive Officer's Office at NanoCarrier Co., Ltd. since January 2015 until N ...
|Chief Business Officer and Director||11.7yrs||no data||no data|
|Director||23.7yrs||no data||1.53% ¥2.2m|
|External Director||23.7yrs||no data||0.48% ¥672.9k|
|External Director||16.7yrs||no data||0.028% ¥39.1k|
|External Auditor||20.3yrs||no data||0.044% ¥61.9k|
|External Auditor||13.4yrs||no data||no data|
|External Director||7.9yrs||no data||no data|
|External Director||5.7yrs||no data||no data|
|Director||0.7yrs||no data||0.068% ¥96.1k|
|Audit & Supervisory Board Member||0yrs||no data||0.00015% ¥211.5|
Experienced Board: 3NQ's board of directors are seasoned and experienced ( 13.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.5%.
NanoCarrier Co., Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: NanoCarrier Co., Ltd.
- Ticker: 3NQ
- Exchange: DB
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: JP¥17.109b
- Listing Market Cap: JP¥141.011m
- Shares outstanding: 66.06m
- Website: https://www.nanocarrier.co.jp
Number of Employees
- NanoCarrier Co., Ltd.
- Chuou 144-15
- 226-39 Wakashiba
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|4571||TSE (The Tokyo Stock Exchange)||Yes||Common Shares||JP||JPY||Mar 2008|
|3NQ||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Mar 2008|
NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceutical products using micellar nanoparticle technology primarily for the treatment of cancer in Japan. Its product pipeline includes NC-6004 Cisplatin micelle for the treatment of pancreatic, head and neck, non-small cell lung, bladder, and biliary track cancers; and VB-111, a non-replicating Adeno 5 vector for the treatment of rGBM/ovarian cancer, etc. The company’s product pipeline also comprise NC-6300 Epirubicin micelle for soft tissue sarcoma; NC-4016 Dach-platinum micelle for solid cancers; and NK105 Paclitaxel micella for the treatment of breast and gastric cancers. NanoCarrier Co., Ltd. was founded in 1996 and is headquartered in Kashiwa, Japan.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/23 21:33|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.